分享好友 资讯首页 频道列表

Divi’s Laboratories Selects Juniper Networks for Automated Network Infrastructure Across Massive Pharma Manufacturing Facilities

2023-02-22 09:0017440

A Juniper-powered network enables Divi's Labs to realize enhanced operational efficiencies and improved network experiences for its workforce of over 17,000 employees

HYDERABAD, India -- (BUSINESS WIRE) --

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Divi’s Laboratories (NSE: DIVISLAB), one of the largest active pharmaceutical ingredients (API) companies globally, has selected Juniper to deliver highly available, ultra-reliable networking solutions across its manufacturing operations, the largest API manufacturing facilities in the world.

Headquartered in Hyderabad, India, Divi’s Labs strategically partners with many of the world’s leading pharma companies, manufacturing and custom synthesizing APIs for products used in over 95 countries including antidepressants, blood pressure medicine, antihistamines and more. In addition, its nutraceutical division also makes vitamins and beta-carotenes used in supplements, food and beverages sold across the world.

Divi’s currently operates two manufacturing sites which run 24/7 near Hyderabad and Visakhapatnam in India, with a third under construction. Collectively, these operations make up the largest API manufacturing facilities globally, with a gross total of 14,500sqm of manufacturing space spread across over 64 buildings in the two sites.

Due to its stringent quality-control processes, Divi's required an ultra-reliable network that could securely transfer data at line rate between its two plants without any packet loss. After experiencing difficulties managing and monitoring its network with their previous legacy solution, it decided to embark on a network refresh with Juniper that would future-proof several operational requirements.

This network refresh would include reliable Power-over-Ethernet (PoE) and PoE+ switching to drive their wireless infrastructure while providing for organizational-wide network visibility, easy onboarding and manageability. Furthermore, Divi's Labs required high-capacity uplinks and multigigabit downlinks to meet growing data exchange needs, as well as the ability to reduce power consumption to meet Divi's sustainability commitments.

Within each site, Divi’s Labs utilizes the EX4600 as Core/Distribution switches, while EX3400 and EX2300 switches provide connectivity to critical network resources including Wi-Fi Access Points. In addition, their data center also fully runs on Juniper gear, driving critical manufacturing processes like formula management, batch tracking, quality control, compliance tracking and even production scheduling.

Across the network, MACsec encryption on the EX switches provides crucial point-to-point security, while Juniper Virtual Chassis technology has also allowed Divi’s IT teams to swiftly and easily configure, manage and upgrade multiple EX switches as if they were a single device.

The network upgrades from Juniper have provided Divi’s Labs with a highly secure, highly available and ultra-reliable network to continue producing world-class APIs. This is crucial as its business continues to scale up, especially in the pharmaceutical sector where life-saving drugs are created round-the-clock and in which uptime is paramount to ensure the most stringent of quality controls.

For Divi’s Labs, dropped packets and network interruptions are now a thing of the past.

Supporting Quotes:

“Especially in recent years, we have seen just how critical the pharma industry’s place is in our global ecosystem. We are excited to be able to partner with Divi’s Labs and to power a dependable, efficient, and highly secure IT infrastructure across their manufacturing operations. We remain committed to enabling them to deliver even more innovative services to their employees and customers.”

- Sajan Paul, Managing Director & Country Manager, India & SAARC, Juniper Networks

“Quality is at the heart of our business. With our manufacturing operations running 24/7, network services are mission-critical with any disruptions having the potential to cause significantly negative impact on production. We are delighted to have found a partner in Juniper who can deliver a reliable, flexible, and secure network across our facilities. This has in-turn allowed us to focus on supporting our production, research, development, and quality control operations – all crucial towards delivering our world-class APIs for critical pharma products utilized across the world.”

- Manoranjan Jasti, Chief Information Officer, Divi’s Laboratories

Additional Resources:

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security, and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability, and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

category-enterprise

View source version on businesswire.com: https://www.businesswire.com/news/home/20230220005010/en/

CONTACT:

Media Relations:
Kenneth Chew
Juniper Networks
+65 6959 0553
kchew@juniper.net

反对 0
举报 0
收藏 0
打赏 0
评论 0
一线黑色素瘤新选择:西达本胺联合纳武利尤单抗全球III期临床降低27%疾病进展风险
联合治疗组与纳武利尤单抗组mPFS的HR为0.73,差异具有统计学显著性和临床意义,肩并肩优于同线方案的历史研究数据。联合方案有望为黑色素瘤患者提供一种不同于双免疫治疗、安全性可预测的新选择。 脑转移是黑色素瘤最主要致死原因。此前于ESMO 2025年会公布的开放队列研究显示,西达本胺联合方案在这一人群中展现积极疗效信号。 微芯生物合作方HUYABIO拟向FDA更新数据,并接洽商业合作伙伴。 西班牙马德里--(美国商业资讯)-- 2026年欧洲肿瘤内科学会(ESMO)年会正于西班牙马...

0评论2026-10-271691

Galderma’s Relfydess (relabotulinumtoxinA) Receives Approval in China for Frown Lines
The Chinese National Medical Products Administration (NMPA) has approved Relfydess, the first and only ready-to-use liquid neuromodulator designed with PEARL Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines...

0评论2026-10-271370

拉斯海玛酋长为首家拉斯海玛在华商务咨询机构揭幕,深化与广东的合作
中国广州--(美国商业资讯)--阿联酋联邦最高委员会成员、拉斯海玛酋长谢赫·萨乌德·本·萨克尔·卡西米殿下为该酋长国首家驻华商务咨询公司揭幕,开启双方合作的新篇章。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20261021003496/zh-CN/ 该机构位于工业重镇广州,将作为拉斯海玛对接中国企业的重要平台,推动双方在重点领域拓展合作。 此次揭...

0评论2026-10-271790

Mundipharma宣布,ReSPECT III期临床试验的补充研究结果已在2026 年IDWeek 会议上作为最新突破性研究口头报告进行展示
仅限贸易及医疗媒体 英国剑桥--(美国商业资讯)-- Mundipharma今日公布了全球ReSPECT III期临床试验的补充研究结果。该试验旨在评估 REZZAYO® (醋酸雷扎芬净)在接受异基因造血干细胞移植(allo-HSCT)的成人患者中预防侵袭性真菌病(IFD)的疗效。上述III期试验数据已于今日作为最新突破性研究口头报告,在IDWeek 2026大会上正式展示。 该报告在此前(2026年4月)公布的ReSPECT试验主要结果基础之上,补充了更多细节数据,包括进一步的终...

0评论2026-10-271308

Energy Impact Partners深化与新加坡经济发展局合作,推动能源创新与脱碳
EIP与新加坡经济发展局(EDB)扩大合作,将EIP的全球网络与新加坡能源转型及脱碳生态系统相连接 该合作通过为高潜力企业打造在新加坡发展壮大的路径,支持新加坡的“脱碳重大挑战计划” 纽约和新加坡--(美国商业资讯)--全球能源投资机构Energy Impact Partners (EIP)与新加坡经济发展局(EDB)今日宣布深化合作伙伴关系,共同推动新加坡的能源创新与脱碳进程。该消息在首届2026年新加坡产业脱碳论坛上公布,该论坛由EDB、新加坡科技研究局(A*STAR)以及先进能源与...

0评论2026-10-271310

Brenus Pharma新型体内免疫疗法STC-1010在一线MSS型转移性结直肠癌中显示出安全性并激活T细胞,2例患者实现完全缓解
ESMO 2026上公布的BreAK CRC-001 Ia期研究:43%的患者最初均不可切除,治疗后转为符合手术条件 海报编号1023P – 开发性治疗学 马德里--(美国商业资讯)--临床阶段生物科技公司Brenus Pharma公布了BreAK CRC-001研究Ia期剂量递增试验的首批数据。共有9名不可切除患者接受治疗;其中89%伴有肝转移,89%为KRAS突变肿瘤,该人群通常对免疫治疗耐药。中位随访时间为8个月(范围1–14个月;数据截止日期为2026年8月6日)。 ...

0评论2026-10-271613

Lifezone Metals确认与Orion CMC就Kabanga镍矿项目开展的谈判已进入后期阶段
纽约--(美国商业资讯)-- Lifezone Metals Limited(纽约证券交易所代码:LZM)注意到,Orion Resource Partners创始人兼集团首席执行官Oskar Lewnowski今日在接受Bloomberg Television采访时,谈及本公司位于坦桑尼亚的Kabanga镍矿项目。 针对采访播出后媒体和投资者的问询,本公司确认,与Orion Critical Mineral Consortium(Orion CMC)就Kabanga镍矿项目一项大额股权...

0评论2026-10-271510

SBC Medical啟動DNA甲基化檢測研發,用於評估生物年齡
憑藉Waqoo Group的科研與技術生態,為主動健康管理與健康長壽建立全新個人基準 加州爾灣--(美國商業資訊)-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC)(簡稱「公司」或「SBC Medical」)是一家在多個醫療保健領域提供管理支援的醫療服務機構(MSO)。公司今日宣布,已啟動一項檢測技術的自主研發,旨在透過DNA甲基化分析評估個人生物年齡。 本新聞稿包含多媒體資訊。完整新聞稿請見此: https://www.bus...

0评论2026-10-262044

沙特海事与物流大会聚焦海事行业协同及沙特贸易投资增长机遇
沙特阿拉伯吉达--(美国商业资讯)--沙特海事与物流大会在吉达超级穹顶会展中心开幕,汇聚政府机构代表、海运与物流行业领袖及工商界人士,重点探讨沙特阿拉伯在保障贸易畅通、增强供应链韧性方面可发挥的作用。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20261022270299/zh-CN/ 当前,贸易和航运形势快速变化,促使企业重新评估运输路线、运营方案和投资选择。本届大会为各方提供交流平台,探讨合作机遇,加强...

0评论2026-10-261942

Tigo Energy TS4产品线全面兼容Fronius,为太阳能安装商带来更多配置选择
Tigo MLPE全面兼容Fronius多款逆变器系列,助力全球太阳能安装商灵活打造高品质、定制化的光伏系统。 洛斯加托斯,加利福尼亚州--(美国商业资讯)--智能太阳能与能源软件解决方案的领先供应商Tigo Energy, Inc.(NASDAQ: TYGO)(以下简称“Tigo”或“公司”)今日宣布,已获得 Fronius International GmbH出具的制造商兼容性声明,确认Tigo Flex MLPE产品与多款Fronius逆变...

0评论2026-10-261766